From Caging to Uncaging With Bioadaptors: A Novel Paradigm in Coronary Revascularization

Area of Science:

• Interventional Cardiology
• Biomaterials Science
• Vascular Biology

Background:

• Conventional drug-eluting stents improve percutaneous coronary intervention (PCI) outcomes but have limitations like late adverse events and impaired vessel function.
• Restoring natural vessel motion and compliance is crucial for optimal long-term results in treating coronary artery disease.

Purpose of the Study:

• To evaluate the safety and efficacy of the DynamX coronary bioadaptor, a novel device designed to restore physiological vessel motion after PCI.
• To compare the performance of the DynamX bioadaptor against traditional drug-eluting stents in preclinical and clinical settings.

Main Methods:

• Preclinical studies assessed vessel stress and rotational motion post-implantation.
• Clinical trials (DYNAMIX, BIOADAPTOR-RCT, INFINITY-SWEDEHEART) evaluated patient outcomes, including imaging, lumen preservation, neointimal hyperplasia, and target-lesion failure rates at various time points.

Main Results:

• Preclinical data showed reduced vessel stress and restored physiological motion.
• The DYNAMIX study demonstrated increased vessel area, optimal strut apposition, and complete neointimal coverage at 12 months.
• Clinical trials indicated noninferiority to drug-eluting stents, with superior late lumen preservation, reduced neointimal hyperplasia, and low target-lesion failure rates, with events plateauing after 6 months.

Conclusions:

• The DynamX coronary bioadaptor provides mechanical support while restoring natural vessel motion, compliance, and pulsatility.
• It represents a significant advancement in PCI, potentially overcoming limitations of current drug-eluting stents.
• Further research is needed to establish its long-term efficacy and role in complex coronary anatomies.